MA27026A1 - Composition pharmaceutique liquide - Google Patents

Composition pharmaceutique liquide

Info

Publication number
MA27026A1
MA27026A1 MA27406A MA27406A MA27026A1 MA 27026 A1 MA27026 A1 MA 27026A1 MA 27406 A MA27406 A MA 27406A MA 27406 A MA27406 A MA 27406A MA 27026 A1 MA27026 A1 MA 27026A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
MA27406A
Other languages
English (en)
Inventor
Neema Mahesh Kulkarni
Michael Schneider
Steven Bernard Silbering
Hans Richard Meyer-Wonnay
Sanii-Yahyai Nahid
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27026A1 publication Critical patent/MA27026A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MA27406A 2001-05-25 2003-11-19 Composition pharmaceutique liquide MA27026A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29383201P 2001-05-25 2001-05-25
US34373301P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
MA27026A1 true MA27026A1 (fr) 2004-12-20

Family

ID=26968180

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27406A MA27026A1 (fr) 2001-05-25 2003-11-19 Composition pharmaceutique liquide

Country Status (44)

Country Link
US (2) US20020198261A1 (fr)
EP (1) EP1395242B1 (fr)
JP (1) JP2004534764A (fr)
KR (1) KR100582963B1 (fr)
CN (1) CN100346779C (fr)
AP (1) AP1815A (fr)
AR (1) AR033922A1 (fr)
AT (1) ATE334656T1 (fr)
AU (1) AU2002258026B2 (fr)
BG (1) BG108376A (fr)
BR (1) BR0209973A (fr)
CA (1) CA2446574C (fr)
CR (1) CR7150A (fr)
CY (1) CY1105147T1 (fr)
CZ (1) CZ299755B6 (fr)
DE (1) DE60213592T2 (fr)
DK (1) DK1395242T3 (fr)
DO (1) DOP2002000403A (fr)
EA (1) EA008087B1 (fr)
EE (1) EE200300587A (fr)
EG (1) EG24078A (fr)
ES (1) ES2265040T3 (fr)
GE (1) GEP20053620B (fr)
HK (1) HK1062646A1 (fr)
HR (1) HRP20030833B1 (fr)
HU (1) HUP0401366A2 (fr)
IL (1) IL158359A0 (fr)
IS (1) IS2428B (fr)
MA (1) MA27026A1 (fr)
MX (1) MXPA03009392A (fr)
MY (1) MY128615A (fr)
NO (1) NO20035200L (fr)
NZ (1) NZ529173A (fr)
OA (1) OA12604A (fr)
PA (1) PA8545901A1 (fr)
PE (1) PE20030087A1 (fr)
PL (1) PL366384A1 (fr)
PT (1) PT1395242E (fr)
RS (1) RS87203A (fr)
SI (1) SI1395242T1 (fr)
SK (1) SK286227B6 (fr)
SV (1) SV2003001053A (fr)
WO (1) WO2002094220A1 (fr)
ZA (1) ZA200308393B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (fr) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba et ses derives utilises pour le traitement de la douleur
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2004016260A1 (fr) * 2002-08-15 2004-02-26 Pfizer Limited Utilisation therapeutique d'acides amines bicycliques ou tricycliques
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
CA2451267A1 (fr) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
EP1480631B1 (fr) * 2002-12-20 2007-08-01 Dynogen Pharmaceuticals Inc. Methodes de traitement de troubles de la vessie non douloureux au moyen de modulateurs de la sous unite alpha-2-delta- du canal calcique
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
RU2320369C2 (ru) * 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
CN1867359B (zh) * 2003-10-08 2010-12-15 马林克罗特公司 哌甲酯溶液及其制药用途和制备方法
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
EP1543831A1 (fr) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
DE102004015752B4 (de) * 2004-03-31 2007-04-05 Christian-Albrechts-Universität Zu Kiel Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen
EP1806133A1 (fr) * 2004-10-14 2007-07-11 Daikin Industries, Ltd. Méthode de modification de l atmosphère d une pièce, et liquide pour pulvérisateur et pulvérisateur employés dans ladite méthode
JP2009504613A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2246044A1 (fr) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Solutions pédiatriques de bêta-bloquants
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) * 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2923694B1 (fr) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Solution pharmaceutique liquide orale de gabapentine
CN104940930A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫药物口服乳剂及其制备方法
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3668508A1 (fr) 2017-08-19 2020-06-24 FTF Pharma Private Limited Composition pharmaceutique orale comprenant du zonisamide et son procédé de préparation
WO2019186515A1 (fr) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Compositions pharmaceutiques liquides de médicaments anti-épileptiques
US20230255885A1 (en) * 2018-08-18 2023-08-17 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
US20210308044A1 (en) 2018-08-18 2021-10-07 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2020193864A1 (fr) 2019-03-26 2020-10-01 Orion Corporation Formulations de prégabaline et leur utilisation
JPWO2022168968A1 (fr) * 2021-02-05 2022-08-11
WO2023034269A1 (fr) * 2021-08-31 2023-03-09 Avion Pharmaceuticals, Llc Poudre de gabapentine stable

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
ID27724A (id) * 1998-05-15 2001-04-26 Warner Lambert Co Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya
WO2002043762A2 (fr) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combinaison d'agonistes gaba et d'inhibiteurs de la sorbitol-deshydrogenase (sdi)

Also Published As

Publication number Publication date
MXPA03009392A (es) 2004-01-29
PT1395242E (pt) 2006-11-30
JP2004534764A (ja) 2004-11-18
SV2003001053A (es) 2003-03-18
SI1395242T1 (en) 2006-10-31
HRP20030833A2 (en) 2004-08-31
CN1509165A (zh) 2004-06-30
CA2446574C (fr) 2008-04-01
HUP0401366A2 (hu) 2004-11-29
DOP2002000403A (es) 2002-11-30
NO20035200D0 (no) 2003-11-24
PA8545901A1 (es) 2003-09-05
EA200301152A1 (ru) 2004-04-29
CR7150A (es) 2004-02-23
BR0209973A (pt) 2004-04-06
AR033922A1 (es) 2004-01-07
IS2428B (is) 2008-10-15
EA008087B1 (ru) 2007-02-27
CZ299755B6 (cs) 2008-11-12
ATE334656T1 (de) 2006-08-15
SK14112003A3 (sk) 2004-08-03
EG24078A (en) 2008-05-11
KR20040003006A (ko) 2004-01-07
AP2003002907A0 (en) 2003-12-31
CN100346779C (zh) 2007-11-07
US20040072904A1 (en) 2004-04-15
DK1395242T3 (da) 2006-10-30
CY1105147T1 (el) 2010-03-03
SK286227B6 (sk) 2008-05-06
DE60213592T2 (de) 2007-08-09
WO2002094220A1 (fr) 2002-11-28
EP1395242B1 (fr) 2006-08-02
HRP20030833B1 (en) 2007-04-30
NO20035200L (no) 2003-11-24
PE20030087A1 (es) 2003-02-14
BG108376A (bg) 2005-04-30
IL158359A0 (en) 2004-05-12
ES2265040T3 (es) 2007-02-01
DE60213592D1 (de) 2006-09-14
AP1815A (en) 2008-01-04
GEP20053620B (en) 2005-09-26
US7256216B2 (en) 2007-08-14
NZ529173A (en) 2005-07-29
CA2446574A1 (fr) 2002-11-28
EP1395242A1 (fr) 2004-03-10
RS87203A (en) 2006-10-27
PL366384A1 (en) 2005-01-24
HK1062646A1 (en) 2004-11-19
OA12604A (en) 2006-06-08
EE200300587A (et) 2004-02-16
AU2002258026B2 (en) 2007-08-02
IS6986A (is) 2003-10-09
MY128615A (en) 2007-02-28
ZA200308393B (en) 2005-04-26
KR100582963B1 (ko) 2006-05-24
US20020198261A1 (en) 2002-12-26
CZ20033066A3 (cs) 2004-08-18

Similar Documents

Publication Publication Date Title
MA27026A1 (fr) Composition pharmaceutique liquide
FI20011478A0 (fi) Farmaseuttinen koostumus
ATE298634T1 (de) Flüssigkeitszerstäuber
MA26937A1 (fr) Nouvelle composition pharmaceutique.
NO20033384D0 (no) Farmasöytisk formulering
NO20033785L (no) Farmasöytisk formulering
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
FI20022128A0 (fi) Farmaseuttinen koostumus
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
FR2820994B1 (fr) Applicateur de liquide
DE60212587D1 (de) Flüssigkeitsspender
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
NO20015534D0 (no) Farmasöytisk blandeapparat
NO20033073D0 (no) Farmasöytisk sammensetning inneholdende citalopram
DE60205375D1 (de) Flüssigkeitsspender
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DE60204167D1 (de) Flüssigkeitsspender
NO20041236L (no) Farmasoytisk formulering
FI5468U1 (fi) Farmaseuttinen koostumus
UA6051S (uk) Контейнер для рідини
UA5826S (uk) Контейнер для рідини
SE0100847D0 (sv) Novel pharmaceutical composition
SE0102572D0 (sv) Pharmaceutical formulation